摘要
目的 探讨启膈散加减方联合TS化疗方案治疗中晚期食管鳞癌(ESCC)的临床疗效及安全性.方法 选取2019年 1 月至 2022 年 6 月于扬州市中医院诊治的 80 例中晚期ESCC患者为研究对象,采用随机分组的方法分为对照组与观察组,各40 例.对照组给予TS方案化疗,观察组在对照组基础上采用启膈散加减方治疗.比较两组患者临床疗效、中医证候积分、血清肿瘤标志物水平、不良反应.结果 观察组治疗有效率为90.0%,明显高于对照组的 72.5%(P＜0.05).治疗后两组吞咽困难、疼痛、声音嘶哑、食欲减退、消瘦乏力、呕吐涎沫评分较治疗前降低,且观察组低于对照组,差异有统计学意义(P＜0.05).治疗后,两组血清鳞状细胞癌抗原(SSCAg)水平低于治疗前,且观察组血清SSCAg水平低于对照组,差异有统计学意义(P＜0.05);两组血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原 125(CA125)、糖类抗原724(CA724)水平组内及组间比较差异无统计学意义(P＞0.05).两组治疗后不良反应发生率比较差异无统计学意义(P＞0.05).结论 启膈散加减方联合TS化疗方案治疗ESCC临床疗效显著,可有效改善临床症状,且安全性较高.
Abstract
Objective To explore the clinical efficacy and safety of Qige pulvis plus minus formula combined with TS chemotherapy in the treatment of advanced esophageal squamous cell carcinoma(ESCC).Methods Eighty patients with advanced ESCC treated and treated in Yangzhou Hospital of Traditional Chinese Medicine from January 2019 to June 2022 were selected as the study objects,and were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with TS chemotherapy,and the observation group was treated with Qige pulvis plus minus formula on the basis of the control group.The clinical efficacy,TCM syndrome score,serum tumor marker level and adverse reactions were compared between the two groups.Results The effective rate of the observation group was 90.0%,which was significantly higher than that of the control group(72.5%)(P＜0.05).After treatment,the scores of dysphagia,pain,hoarseness,loss of appetite,emaciation,and saliva vomiting in the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P＜0.05).After treatment,serum squamous cell carcinoma antigen(SSCAg)level in 2 groups was lower than before treatment,and serum SSCAg level in observation group was lower than control group,the difference was statistically significant(P＜0.05).There was no significant difference in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)and carbohydrate antigen 724(CA724)between the two groups(P＞0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P＞0.05).Conclusion Qige pulvis plus minus formula combined with TS chemotherapy has significant clinical efficacy in the treatment of ESCC,and can effectively improve clinical symptoms with high safety.
国家科技期刊平台
NSTL
万方数据